{
    "title": "HLA-Aâ˜…3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans",
    "pmid": "21428769",
    "pmcid": "PMC3113609",
    "study_parameters": [
        {
            "Study Parameters ID": 1184466924,
            "Variant Annotation ID": 1184466922,
            "Study Type": "case/control",
            "Study Cases": 12.0,
            "Study Controls": 257.0,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 8.0E-5",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 25.93,
            "Confidence Interval Start": 4.93,
            "Confidence Interval Stop": 116.18,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": "1184466922"
        },
        {
            "Study Parameters ID": 1184466918,
            "Variant Annotation ID": 1184466916,
            "Study Type": "case/control",
            "Study Cases": 106.0,
            "Study Controls": 257.0,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 8.0E-7",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 8.33,
            "Confidence Interval Start": 3.59,
            "Confidence Interval Stop": 19.36,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": "1184466916"
        },
        {
            "Study Parameters ID": 1184466915,
            "Variant Annotation ID": 1184466909,
            "Study Type": "case/control",
            "Study Cases": 27.0,
            "Study Controls": 257.0,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.03",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 12.41,
            "Confidence Interval Start": 1.27,
            "Confidence Interval Stop": 121.03,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": "1184466909"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1184466922,
            "Variant/Haplotypes": "HLA-A*31:01",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 21428769,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). 42% (5/9) of subjects with carbamazepine-induced SJS/TEN carried the *31:01 allele, as compared to 4% (10/257) of carbamazepine-tolerant controls.",
            "Sentence": "HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.",
            "Alleles": "*31:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Disease:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21428769",
            "Variant Annotation ID_norm": "1184466922"
        },
        {
            "Variant Annotation ID": 1184466916,
            "Variant/Haplotypes": "HLA-A*31:01",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 21428769,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Patients with carbamazepine-induced maculopapular exanthema had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.",
            "Sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.",
            "Alleles": "*31:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Disease:Maculopapular Exanthema",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21428769",
            "Variant Annotation ID_norm": "1184466916"
        },
        {
            "Variant Annotation ID": 1184466909,
            "Variant/Haplotypes": "HLA-A*31:01",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 21428769,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Hypersensitivity syndrome defined as the presence of a rash or liver involvement within 3 months after initiation of carbamazepine treatment, along with a minimum of two of the following manifestations: prolonged recovery phase despite drug withdrawal, fever, involvement of other internal organs, or presence of hematologic abnormalities. Patients who experienced carbamazepine-induced hypersensitivity syndrome had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.",
            "Sentence": "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.",
            "Alleles": "*31:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Disease:Drug Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21428769",
            "Variant Annotation ID_norm": "1184466909"
        }
    ],
    "var_fa_ann": []
}